Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation

Retrieved on: 2024-06-21 21:11:48

Tags for this article:

Click the tags to see associated articles and topics

Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation. View article details on hiswai:

Excerpt

Poster presented at: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference; June 8-10, 2024; Chicago, IL. Lilly reports first ...

Article found on: www.dermatologytimes.com